Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 13;12(9):4081-4109.
doi: 10.7150/thno.70853. eCollection 2022.

Advances in the polymeric delivery of nucleic acid vaccines

Gang Chen  1 , Bowen Zhao  2 , Elena F Ruiz  2 , Fuwu Zhang  2   3
Affiliations
Review

Advances in the polymeric delivery of nucleic acid vaccines

Gang Chen et al. Theranostics. .

Abstract

Nucleic acid vaccines, especially messenger RNA (mRNA) vaccines, display unique benefits in the current COVID-19 pandemic. The application of polymeric materials as delivery carriers has greatly promoted nucleic acid vaccine as a promising prophylactic and therapeutic strategy. The inherent properties of polymeric materials render nucleic acid vaccines with excellent in vivo stability, enhanced biosafety, specific cellular uptake, endolysosomal escape, and promoted antigen expression. Although polymeric delivery of nucleic acid vaccines has progressed significantly in the past decades, clinical translation of polymer-gene vaccine systems still faces insurmountable challenges. This review summarizes the diverse polymers and their characterizations and representative formulations for nucleic acid vaccine delivery. We also discussed existing problems, coping strategies, and prospect relevant to applications of nucleic acid vaccines and polymeric carriers. This review highlights the rational design and development of polymeric vaccine delivery systems towards meeting the goals of defending serious or emerging diseases.

Keywords: cellular immunity; gene delivery; humoral immunity; nucleic acid vaccine; polymer.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Representative polymeric formulations used for vaccine delivery including polyplex, micelle, lipopolyplex, polymer engineered inorganic nanoparticles (NPs), hydrogel, and microneedle.
Figure 2
Figure 2
A. Chemical structure of chitin. B. Chemical structure of chitosan.
Figure 3
Figure 3
A. Chemical structure of linear PLL. B. Chemical structure of branched PLL.
Figure 4
Figure 4
A. Chemical structure of linear PEI. B. Chemical structure of branched PEI.
Figure 5
Figure 5
A. Chemical structure of PBAE. B. Chemical structure of PLGA.
Figure 6
Figure 6
A. Chemical structure of PAMAM. B. Chemical structure of pABOL.
Figure 7
Figure 7
Schematic illustrations of the concept of multifunctional core-shell polymeric NPs: transdermal DNA delivery, tracking of Langerhans cell migration, a pH-mediated DNA release mechanism, and gene expression in LNs. Adapted with permission from , copyright 2010 Elsevier.
Figure 8
Figure 8
A. GO and low molecular weight PEI (LPEI) are fabricated to form the injectable hydrogel (GLP-RO Gel) to encapsulate mRNA and R848. B. Illustration of the treatment intervals. C. Growth curves, D. gross images, and E. weight of tumors. F. H&E images of tumor tissues. G. Flow cytometry analysis of T cells in splenocytes. H. ELISA analysis of TNF-α and I. OVA-specific IgG in serum. Adapted with permission from , copyright 2021 American Chemical Society.
Figure 9
Figure 9
Representative microneedles including coated, dissolvable/degradable, and smart microneedles.
Figure 10
Figure 10
A. Deoxycholic acid conjugated LPEI (DA-LPEI) was applied to encapsulate R848 and S- or N-protein encoding DNA vaccines (DLP-RS or RN). B. The backing layer of microneedles can be separated from the skin and leave the microneedles in the skin by controlling temperature. C. Physiological mechanism of separable microneedle patch mediated antiviral immunity. Adapted with permission from , copyright 2021 American Chemical Society.
Figure 11
Figure 11
Summary of strategies for enhancing the efficacy of nucleic acid vaccines.
Figure 12
Figure 12
Different immunization routes (i.e. intradermal vaccination, subcutaneous vaccination, intramuscular vaccination, intravenous injection, mucosal administration, and intranodal injection) and APC (in the middle) uptake.
See this image and copyright information in PMC

References

    1. Valencic E, Smid A, Jakopin Z, Tommasini A, Mlinaric-Rascan I. Repositioning drugs for rare immune diseases: Hopes and challenges for a precision medicine. Curr Med Chem. 2018;25:2764–82. - PubMed
    1. Whitworth HS, Gallagher KE, Howard N, Mounier-Jack S, Mbwanji G, Kreimer AR. et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. Vaccine. 2020;38:1302–14. - PubMed
    1. Minor PD. Live attenuated vaccines: Historical successes and current challenges. Virology. 2015;479-480:379–92. - PubMed
    1. Excoffon K. The coxsackievirus and adenovirus receptor: Virological and biological beauty. FEBS Lett. 2020;594:1828–37. - PubMed
    1. Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Meel R. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16:630–43. - PubMed

Publication types